Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
      Description

      This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.

      Conditions
      Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent EctomesenchymomaRecurrent EpendymomaRecurrent Ewing SarcomaRecurrent HepatoblastomaRecurrent Kidney Wilms TumorRecurrent Langerhans Cell HistiocytosisRecurrent Malignant Germ Cell TumorRecurrent Malignant GliomaRecurrent MedulloblastomaRecurrent MelanomaRecurrent NeuroblastomaRecurrent Non-Hodgkin LymphomaRecurrent OsteosarcomaRecurrent Peripheral Primitive Neuroectodermal TumorRecurrent Rhabdoid TumorRecurrent Rhabdoid Tumor of the KidneyRecurrent RhabdomyosarcomaRecurrent Soft Tissue SarcomaRecurrent Thyroid Gland CarcinomaRecurrent WHO Grade 2 GliomaRefractory Adrenal Gland PheochromocytomaRefractory EpendymomaRefractory Ewing SarcomaRefractory HepatoblastomaRefractory Langerhans Cell HistiocytosisRefractory Malignant Germ Cell TumorRefractory Malignant GliomaRefractory MedulloblastomaRefractory MelanomaRefractory NeuroblastomaRefractory Non-Hodgkin LymphomaRefractory OsteosarcomaRefractory Peripheral Primitive Neuroectodermal TumorRefractory Rhabdoid TumorRefractory Rhabdoid Tumor of the KidneyRefractory RhabdomyosarcomaRefractory Soft Tissue SarcomaRefractory Thyroid Gland CarcinomaRefractory WHO Grade 2 Glioma
      Talk to us